239 related articles for article (PubMed ID: 29601088)
1. Blocking H1/H2 histamine receptors inhibits damage/fibrosis in Mdr2
Kennedy L; Hargrove L; Demieville J; Karstens W; Jones H; DeMorrow S; Meng F; Invernizzi P; Bernuzzi F; Alpini G; Smith S; Akers A; Meadows V; Francis H
Hepatology; 2018 Sep; 68(3):1042-1056. PubMed ID: 29601088
[TBL] [Abstract][Full Text] [Related]
2. Ursodeoxycholate inhibits mast cell activation and reverses biliary injury and fibrosis in Mdr2
Meng F; Kennedy L; Hargrove L; Demieville J; Jones H; Madeka T; Karstens A; Chappell K; Alpini G; Sybenga A; Invernizzi P; Bernuzzi F; DeMorrow S; Francis H
Lab Invest; 2018 Nov; 98(11):1465-1477. PubMed ID: 30143751
[TBL] [Abstract][Full Text] [Related]
3. Amelioration of Large Bile Duct Damage by Histamine-2 Receptor Vivo-Morpholino Treatment.
Kennedy L; Meadows V; Kyritsi K; Pham L; Kundu D; Kulkarni R; Cerritos K; Demieville J; Hargrove L; Glaser S; Zhou T; Jaeger V; Alpini G; Francis H
Am J Pathol; 2020 May; 190(5):1018-1029. PubMed ID: 32142732
[TBL] [Abstract][Full Text] [Related]
4. Mast cells selectively target large cholangiocytes during biliary injury via H2HR-mediated cAMP/pERK1/2 signaling.
Zhou T; Meadows V; Kundu D; Kyritsi K; Owen T; Ceci L; Carpino G; Onori P; Gaudio E; Wu N; Glaser S; Ekser B; Alpini G; Kennedy L; Francis H
Hepatol Commun; 2022 Oct; 6(10):2715-2731. PubMed ID: 35799467
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of hepatic stem cell factor by Vivo-Morpholino treatment inhibits mast cell migration and decreases biliary damage/senescence and liver fibrosis in Mdr2
Meadows V; Kennedy L; Hargrove L; Demieville J; Meng F; Virani S; Reinhart E; Kyritsi K; Invernizzi P; Yang Z; Wu N; Liangpunsakul S; Alpini G; Francis H
Biochim Biophys Acta Mol Basis Dis; 2019 Dec; 1865(12):165557. PubMed ID: 31521820
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of mast cell-secreted histamine decreases biliary proliferation and fibrosis in primary sclerosing cholangitis Mdr2(-/-) mice.
Jones H; Hargrove L; Kennedy L; Meng F; Graf-Eaton A; Owens J; Alpini G; Johnson C; Bernuzzi F; Demieville J; DeMorrow S; Invernizzi P; Francis H
Hepatology; 2016 Oct; 64(4):1202-1216. PubMed ID: 27351144
[TBL] [Abstract][Full Text] [Related]
7. Biliary damage and liver fibrosis are ameliorated in a novel mouse model lacking l-histidine decarboxylase/histamine signaling.
Kennedy L; Meadows V; Demieville J; Hargrove L; Virani S; Glaser S; Zhou T; Rinehart E; Jaeger V; Kyritsi K; Pham L; Alpini G; Francis H
Lab Invest; 2020 Jun; 100(6):837-848. PubMed ID: 32054995
[TBL] [Abstract][Full Text] [Related]
8. Loss of apical sodium bile acid transporter alters bile acid circulation and reduces biliary damage in cholangitis.
Meadows V; Marakovits C; Ekser B; Kundu D; Zhou T; Kyritsi K; Pham L; Chen L; Kennedy L; Ceci L; Wu N; Carpino G; Zhang W; Isidan A; Meyer A; Owen T; Gaudio E; Onori P; Alpini G; Francis H
Am J Physiol Gastrointest Liver Physiol; 2023 Jan; 324(1):G60-G77. PubMed ID: 36410025
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Mast Cell-Derived Histamine Decreases Human Cholangiocarcinoma Growth and Differentiation via c-Kit/Stem Cell Factor-Dependent Signaling.
Johnson C; Huynh V; Hargrove L; Kennedy L; Graf-Eaton A; Owens J; Trzeciakowski JP; Hodges K; DeMorrow S; Han Y; Wong L; Alpini G; Francis H
Am J Pathol; 2016 Jan; 186(1):123-33. PubMed ID: 26597881
[TBL] [Abstract][Full Text] [Related]
10. Knockdown of vimentin reduces mesenchymal phenotype of cholangiocytes in the Mdr2
Zhou T; Kyritsi K; Wu N; Francis H; Yang Z; Chen L; O'Brien A; Kennedy L; Ceci L; Meadows V; Kusumanchi P; Wu C; Baiocchi L; Skill NJ; Saxena R; Sybenga A; Xie L; Liangpunsakul S; Meng F; Alpini G; Glaser S
EBioMedicine; 2019 Oct; 48():130-142. PubMed ID: 31522982
[TBL] [Abstract][Full Text] [Related]
11. Prolonged darkness reduces liver fibrosis in a mouse model of primary sclerosing cholangitis by miR-200b down-regulation.
Wu N; Meng F; Zhou T; Han Y; Kennedy L; Venter J; Francis H; DeMorrow S; Onori P; Invernizzi P; Bernuzzi F; Mancinelli R; Gaudio E; Franchitto A; Glaser S; Alpini G
FASEB J; 2017 Oct; 31(10):4305-4324. PubMed ID: 28634212
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of p16 Decreases Biliary Damage and Liver Fibrosis in the Mdr2
Kyritsi K; Francis H; Zhou T; Ceci L; Wu N; Yang Z; Meng F; Chen L; Baiocchi L; Kundu D; Kennedy L; Liangpunsakul S; Wu C; Glaser S; Alpini G
Gene Expr; 2020 Nov; 20(2):89-103. PubMed ID: 32393417
[TBL] [Abstract][Full Text] [Related]
13. Knockout of secretin receptor reduces biliary damage and liver fibrosis in Mdr2
Zhou T; Wu N; Meng F; Venter J; Giang TK; Francis H; Kyritsi K; Wu C; Franchitto A; Alvaro D; Marzioni M; Onori P; Mancinelli R; Gaudio E; Glaser S; Alpini G
Lab Invest; 2018 Nov; 98(11):1449-1464. PubMed ID: 29977037
[TBL] [Abstract][Full Text] [Related]
14. Mast Cells Regulate Ductular Reaction and Intestinal Inflammation in Cholestasis Through Farnesoid X Receptor Signaling.
Meadows V; Kennedy L; Ekser B; Kyritsi K; Kundu D; Zhou T; Chen L; Pham L; Wu N; Demieville J; Hargrove L; Glaser S; Alpini G; Francis H
Hepatology; 2021 Nov; 74(5):2684-2698. PubMed ID: 34164827
[TBL] [Abstract][Full Text] [Related]
15. The H4 histamine receptor agonist, clobenpropit, suppresses human cholangiocarcinoma progression by disruption of epithelial mesenchymal transition and tumor metastasis.
Meng F; Han Y; Staloch D; Francis T; Stokes A; Francis H
Hepatology; 2011 Nov; 54(5):1718-28. PubMed ID: 21793031
[TBL] [Abstract][Full Text] [Related]
16. Bile duct ligation-induced biliary hyperplasia, hepatic injury, and fibrosis are reduced in mast cell-deficient Kit
Hargrove L; Kennedy L; Demieville J; Jones H; Meng F; DeMorrow S; Karstens W; Madeka T; Greene J; Francis H
Hepatology; 2017 Jun; 65(6):1991-2004. PubMed ID: 28120369
[TBL] [Abstract][Full Text] [Related]
17. Endothelin Receptor-A Inhibition Decreases Ductular Reaction, Liver Fibrosis, and Angiogenesis in a Model of Cholangitis.
Owen T; Carpino G; Chen L; Kundu D; Wills P; Ekser B; Onori P; Gaudio E; Alpini G; Francis H; Kennedy L
Cell Mol Gastroenterol Hepatol; 2023; 16(4):513-540. PubMed ID: 37336290
[TBL] [Abstract][Full Text] [Related]
18. Cholangiocytes in the pathogenesis of primary sclerosing cholangitis and development of cholangiocarcinoma.
Chung BK; Karlsen TH; Folseraas T
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1390-1400. PubMed ID: 28844951
[TBL] [Abstract][Full Text] [Related]
19. Neoplastic Transformation of the Peribiliary Stem Cell Niche in Cholangiocarcinoma Arisen in Primary Sclerosing Cholangitis.
Carpino G; Cardinale V; Folseraas T; Overi D; Grzyb K; Costantini D; Berloco PB; Di Matteo S; Karlsen TH; Alvaro D; Gaudio E
Hepatology; 2019 Feb; 69(2):622-638. PubMed ID: 30102768
[TBL] [Abstract][Full Text] [Related]
20. FGF1 Signaling Modulates Biliary Injury and Liver Fibrosis in the Mdr2
O'Brien A; Zhou T; White T; Medford A; Chen L; Kyritsi K; Wu N; Childs J; Stiles D; Ceci L; Chakraborty S; Ekser B; Baiocchi L; Carpino G; Gaudio E; Wu C; Kennedy L; Francis H; Alpini G; Glaser S
Hepatol Commun; 2022 Jul; 6(7):1574-1588. PubMed ID: 35271760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
